All In Biotech

NDA 217064 · Famygen Life Sci

Ryzumvi

Phentolamine Mesylate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 25, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

46

14 Phase 3, 7 recruiting

FAERS reports

139

91 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 9, 2026.

RYZUMVI is indicated for: • Treatment of presbyopia in adults. • Treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide) in adults and pediatric patients 3 years of age and older. RYZUMVI is an alpha-adrenergic blocker indicated for the: • treatment of presbyopia in adults. ( 1 ) • treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide) in adults and pediatric patients 3 years of age and older. ( 1 )

Mechanism: RYZUMVI is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Physiological dilation of the pupil is primarily controlled by the radial iris dilator muscles surrounding the pupil; these muscles are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors on the iris dilator muscle, thereby reducing pupil diameter, with no effect on the ciliary muscle. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RYZUMVI · PHENTOLAMINE MESYLATE EQ 0.75% BASE · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phentolamine" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ocular hyperaemia20
  • blood urea increased14
  • blood glucose increased13
  • neutrophil count increased13
  • anaemia12
  • diarrhoea12
  • headache12
  • hypertension12
  • lymphocyte count decreased12
  • drug ineffective11
  • dizziness10
  • haemoglobin decreased10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
20076
20081
20093
20102
201115
20125
20141
20152
20164
201715
20184
20194
20203
20215
20224
20233
202420
202526
202612

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 275 on PubMed

Sponsor: Famygen Life Sci

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.